Advertisement
New Zealand markets closed
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NZD/USD

    0.5896
    -0.0010 (-0.17%)
     
  • NZD/EUR

    0.5532
    -0.0012 (-0.22%)
     
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • OIL

    83.29
    +0.56 (+0.68%)
     
  • GOLD

    2,398.40
    +0.40 (+0.02%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,824.28
    -52.77 (-0.67%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,678.97
    -158.43 (-0.89%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • NZD/JPY

    91.0600
    -0.1940 (-0.21%)
     

Pfizer's Sales Could Sink 33% in 2023. Here's Why to Buy the Stock Anyway.

Pfizer's Sales Could Sink 33% in 2023. Here's Why to Buy the Stock Anyway.

Pfizer (NYSE: PFE) enjoyed a record year in 2022. The big drugmaker's revenue topped $100 billion. Its earnings per share soared 42% to $5.47, which translates to nearly $31.4 billion in profits. Both top- and bottom-line numbers set all-time highs.